Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03627715
Other study ID # DMX-200-203 A
Secondary ID ACTRN12618000982
Status Completed
Phase Phase 2
First received
Last updated
Start date November 6, 2018
Est. completion date August 18, 2020

Study information

Verified date February 2020
Source Dimerix Bioscience Pty Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will be evaluating the safety and efficacy of propagermanium for the treatment of participants with DKD who are already taking irbesartan by: - monitoring symptoms that participants may experience while on the study, - measuring levels of protein in participant's urine and kidney function during the course of the study, - measuring the levels of propagermanium and irbesartan that enters into participant's urine and blood, and - comparing the propagermanium outcomes to participants' pre-study and placebo outcomes. Eligible participants will randomly be assigned to one of two arms to receive both the propagermanium and placebo in different orders as follows, either: Treatment Period 1 taking a propagermanium capsule twice a day for 12 weeks, followed by a six week washout period followed by Treatment Period 2 taking a placebo capsule twice a day for 12 weeks. OR Treatment Period 1 taking a placebo capsule twice a day for 12 weeks, followed by a six week washout period followed by Treatment Period 2 taking a propagermanium capsule twice a day for 12 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date August 18, 2020
Est. primary completion date July 23, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: 1. Aged 18 to 90 (inclusive) at screening; 2. A diagnosis of type 2 diabetes mellitus; 3. Baseline glycated haemoglobin (HbA1c) = 12%; 4. Fasting plasma glucose < 21 mmol/L; 5. Must be receiving a stable dose of 300 mg daily of irbesartan (in any marketed formulation) for at least 3 months prior to screening, and have no plan to change treatment regime throughout the study; 6. Patients can be on stable doses of angiotensin converting enzyme inhibitors, aldosterone inhibitors, and/or sodium-glucose co-transporter-2 inhibitors. However, the dose and regimen must be stable for 3 months prior to screening and must have no plan to change treatment regime throughout the study; 7. Mean of two albumin creatinine ratio (ACR) values (screening and baseline) of more than or equal to 265 to 4,425 mg/g (30-500 mg/mmol) and within 30% of the screening value at the baseline assessment; 8. Estimated glomerular filtration rate more than or equal to 25-90 mL/min/1.73 m^2 using chronic kidney disease epidemiology collaboration (CKD-EPI) formula at screening; 9. Serum potassium levels (screening and baseline) less than 5.5 mmol/L. If either value is 5.5 or above the patient may receive dietary advice and be retested one week after the second value 10. A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: - Not of childbearing potential, defined as surgically sterile (documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or postmenopausal (no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone [FSH] level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy; however, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.); - Of childbearing potential and agrees to use a highly effective method of contraception consistently during the treatment period and for at least 60 days after the last dose of investigational product; 11. A male patient with a female partner of childbearing potential is eligible to participate if he agrees to use acceptable contraception during the treatment period and for at least 60 days after the last dose of investigational product and refrains from donating sperm during this period; 12. Have given written informed consent prior to any study procedures being performed. Exclusion Criteria: 1. A history of type 1 diabetes mellitus; 2. Current known non-diabetic renal disease. Patients with a history of other resolved renal diseases must be approved by the Sponsor; 3. A prior organ or stem cell transplant; 4. A major adverse cardiac event within 6 months before screening; 5. Patients receiving immunosuppressive medications including patients receiving > 5 mg prednisone; 6. Rapid estimated glomerular filtration rate decline with renal replacement likely during study 7. Lymphoma, leukaemia, or any malignancy within the past 5 years except for basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ that have been resected with no evidence of metastatic disease for 3 years; 8. Jaundice, active hepatitis, or known hepatobiliary disease (except asymptomatic cholelithiasis); 9. Alanine aminotransferase and/or aspartate aminotransferase more than two times the upper limit of normal at screening; 10. Participation in any clinical study with an experimental medication or device within 90 days or 5 half-lives (whichever is longer) of screening or have previously participated in a study involving propagermanium; 11. Positive screening assessment for viral hepatitis B surface antigen or hepatitis C virus (HCV) antibody AND positive HCV ribonucleic acid or human immunodeficiency virus (HIV); 12. Seated blood pressure of more than or equal to 160/100 mmHg at screening; 13. Body mass index more than or equal to 42 kg/m^2 at screening; 14. Past hospitalisation for a major depressive episode; 15. Is breast feeding or pregnant; 16. Unable to comply with the study procedures and assessments, including the ability swallow capsules; 17. Any other disease, physical or psychological condition that the investigator or sponsor believes may contraindicate the use of the investigational medicinal product or affect the interpretation of study results or render the patient at high risk from treatment complications; 18. Are investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.

Study Design


Intervention

Drug:
Propagermanium
Immediate release capsule
Placebo
Placebo capsule

Locations

Country Name City State
Australia Sunshine Coast University Hospital Birtinya Queensland
Australia Boxhill Hospital Box Hill Victoria
Australia Renal Research Gosford New South Wales
Australia Austin Hospital Heidelberg Victoria
Australia Liverpool Hospital Liverpool New South Wales
Australia Melbourne Renal Research Group Melbourne Victoria
Australia Royal Melbourne Hospital Melbourne Victoria
Australia St Vincents Hospital Melbourne Victoria
Australia Sunshine Hospital Melbourne Victoria
Australia Epworth Hospital Richmond Victoria
Australia Royal North Shore Hospital St Leonards New South Wales
Australia Westmead Hospital Westmead New South Wales
Australia Princess Alexandra Hospital Woolloongabba Queensland

Sponsors (2)

Lead Sponsor Collaborator
Dimerix Bioscience Pty Ltd Iqvia Pty Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Change in Albumin/Creatinine Ratio with Adjunct use of Propagermanium Compared to Placebo in Participants with DKD who are Receiving Irbesartan Assessed by measuring albumin/creatinine ratio. Twelve weeks
Secondary The Effect of Treatment with Propagermanium Compared to Placebo on Measures of Estimated Glomerular Filtration Rate Assessed by measuring estimated glomerular filtration rate. Twelve weeks
Secondary The Number of Adverse Events with the Adjunct use of Propagermanium Adverse events will be recorded by a patient diary and by site staff during site visits. Twelve weeks
Secondary The Effect of Treatment with Propagermanium on Measures of Proteinuria as measured by ACR Assessed by measuring albumin/creatinine ratio at each end point. Eleven 24-hour urine samples at week -2, week -1, week 6, week 11, week 12.
See also
  Status Clinical Trial Phase
Recruiting NCT06006689 - Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis) Phase 2
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT05086549 - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT02276196 - Effect of LIXIsenatide on the Renal System Phase 4
Not yet recruiting NCT06120569 - Evaluate the Role of Soleus Muscle Exercise in Glycaemic Control in Diabetic Kidney Disease Patients N/A
Completed NCT02545049 - Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease Phase 3
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Active, not recruiting NCT06176599 - Clinical Study on the Treatment of Diabetic Kidney Disease With Shenxiao Yuning Decoction With Syndrome of Qi and Yin Deficiency and Blood Stasis N/A
Recruiting NCT03716401 - Prognostic Imaging Biomarkers for Diabetic Kidney Disease
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Completed NCT01377688 - Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes N/A
Active, not recruiting NCT05514548 - Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease Phase 2
Recruiting NCT05507892 - Renal Mechanism of SGLT2 Inhibition Phase 2
Not yet recruiting NCT06049550 - The Influence of the Thickening of Bowman's Capsule on the Clinical Prognosis of Patients With Diabetic Kidney Disease
Not yet recruiting NCT05514184 - Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease N/A
Active, not recruiting NCT04589351 - Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe Phase 3
Active, not recruiting NCT04531163 - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy Phase 2/Phase 3
Active, not recruiting NCT03620773 - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Phase 1/Phase 2
Suspended NCT01878045 - Mechanisms of Diabetic Kidney Disease in American Indians